DelveInsight’s, “Rabies infection – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Rabies infection Understanding
Rabies infection: Overview
Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is caused by a lyssavirus (a form of virus that causes encephalitis) that affects the saliva and nervous system. Most cases of rabies in humans are caused by a bite or scratch from an infected animal. It is possible, but rare, for people to get rabies if infectious material from a rabid animal, such as saliva, gets directly into their eyes, nose, mouth, or a wound. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death. Medical assistance should be obtained as soon as possible after an exposure or possible exposure to rabies. The most effective treatment for rabies is immediate treatment of the wound followed by immunization with the rabies vaccine.

"Rabies infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies infection pipeline landscape is provided which includes the disease overview and Rabies infection treatment guidelines. The assessment part of the report embraces, in depth Rabies infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Rabies infection R&D. The therapies under development are focused on novel approaches to treat/improve Rabies infection.

Rabies infection Emerging Drugs Chapters
This segment of the Rabies infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rabies infection Emerging Drugs
• SYN-023: Synermore Biologics
SYN-023 is a mixture of two anti-rabies humanized monoclonal antibodies, CTB-011 and CTB-012, which bind to 2 different antigenic sites on the rabies glycoprotein. SYN-023 is proposed for use in humans following exposure to the rabies virus. The proposed clinical indication is for post-exposure prophylaxis treatment of rabies in conjunction with rabies vaccine. The proposed mechanism of action is for the mAbs to bind to the rabies virus, which results in virus neutralization in a manner similar to an immune response producing neutralizing antibodies. SYN-023 has been shown to neutralize greater than 15 contemporary wildlife isolates of rabies virus collected in China and 10 isolates collected in the North American. SYN-023 is currently being evaluated in Phase III clinical trial to treat rabies infection.

• Freeze-dried human rabies vaccine: Anhui Zhifei Longcom Biopharmaceutical
Freeze-dried human rabies vaccine (Vero cells) is being developed and investigated by Anhui Zhifei Longcom Biopharmaceutical in Phase III stage of development for the treatment of rabies.
Further product details are provided in the report……..

Rabies infection: Therapeutic Assessment
This segment of the report provides insights about the different Rabies infection drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Rabies infection
There are approx. 10+ key companies which are developing the therapies for Rabies infection. The companies which have their Rabies infection drug candidates in the most advanced stage, i.e. Phase III include, Synermore Biologics.
• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Rabies infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rabies infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rabies infection drugs.

Rabies infection Report Insights
• Rabies infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rabies infection Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Rabies infection drugs?
• How many Rabies infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rabies infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rabies infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rabies infection and their status?
• What are the key designations that have been granted to the emerging drugs?